MP CARDIOFLOW-B (02160) rose more than 6% in Hong Kong trading. As of the time of writing, the stock was up 6.33% to HK$0.84, with a turnover of HK$8.5992 million. The move follows an announcement from the company on the evening of February 13. The announcement stated that China's National Medical Products Administration (NMPA) Center for Medical Device Evaluation had published a review outcome, indicating a preliminary agreement to include the group's new generation implantable cardioverter defibrillator (ICD) product, TILEN/EYLEN, in the Innovative Medical Device Special Review Process, also known as the NMPA Green Channel. Consequently, the TILEN/EYLEN device is expected to become the first MRI-conditional safety ICD with independent intellectual property rights to gain approval in China.